Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$6.4B
65M shares
52-week range
$63.23 – $130.00
50% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
9.9
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
www.mirumpharma.comNo one on the platform currently holds MIRM.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 582,085 | $53.8M |
No one on the platform has traded MIRM yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 54.7% | |||||
| Profit Margin % | -4.5% | -146.6% | ||||
| Free Cash Flow Margin % | 10.5% | -197.0% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $698M | +35.4% | $-15.13 | $-15.51–$-14.22 | — | 7 |
| 2027 | $814M | +16.6% | $-0.76 | $-5.28–$3.06 | — | 7 |
| 2028 | $1.0B | +26.7% | $1.78 | $-0.47–$5.34 | 54.4× | 8 |
| 2029 | $1.4B | +33.9% | $5.16 | $4.76–$5.55 | 18.7× | 5 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $-0.74 | $-1.06 | -42.8% |
| 2026-05-06 | $-0.40 | $-13.43 | -3257.5% |
| 2026-02-25 | $0.02 | $-0.11 | -650.0% |
| 2025-11-04 | $-0.10 | $0.05 | +150.0% |
| 2025-08-06 | $-0.31 | $-0.12 | +61.3% |
| 2025-05-07 | $-0.39 | $-0.30 | +23.1% |
| 2025-02-26 | $-0.27 | $-0.49 | -81.5% |
| 2024-11-12 | $-0.45 |
| $-0.30 |
| +33.3% |
| $3.5B |
| — |
| LGNDLigand Pharmaceuticals Incorporated | $277.82 | -1.01% | $5.6B | — |
| PRAXPraxis Precision Medicines, Inc. | $330.18 | -0.11% | $9.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$MIRM any thoughts on what to expect on PDUFA day(Sept 26th)??
View on StockTwits ↗
Citizens reit'd $MIRM Mkt OP-$137/said The interim AZURE-1 data confirmed our view that brelovitug is a differentiated candidate in the HDV landscape and also substantially derisked the pivotal AZURE-1 and AZURE-4 readouts. $GILD $VIR - ALNY JNJ - GSK ASMB ALGS Here's what else Citizens had to say: https://x.com/Quantumup1/status/2092924222301479170?s=20
View on StockTwits ↗
$MIRM data for HDV coming soon. Think end of Sep. Will Be interesting to see how it compares to SOC and competition.
View on StockTwits ↗BofA🏁 $PRQR and said -- We initiate coverage of ProQR with a Buy rating and $8 PO. $MIRM $IPSEY IONS BofA added—AX-0810 (NTCP, the liver's bile acid transporter) provides the first human validation of Axiomer, ProQR's technology for making precise, temporary RNA changes. ProQR initially targets biliary atresia, a childhood disease where damaged bile ducts can lead to liver failure, affecting roughly 20k patients globally with no approved disease-modifying therapy. '0810 and next-generation '0811 aim to reduce toxic bile acid exposure inside liver cells while preserving NTCP's other functions. This differs from competitors Bylvay (Ipsen) and Livmarli (Mirum), which block intestinal bile acid recycling. Bylvay's recent Phase 3 failure on native liver survival removes a competitor and, in our view, reinforces the need for a liver-directed approach such as ProQR's.
View on StockTwits ↗
$MIRM nice BA and Alagille data. Looking forward to OLE readout! 🤩
View on StockTwits ↗
$MIRM Real-world use of maralixibat in biliary atresia: a case series "In this case series, we observed a meaningful pruritus response in all six patients, with three patients experiencing complete resolution. These results suggest that maralixibat may be a useful treatment option for patients with BA who have cholestatic pruritus". https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2026.1858862/full
View on StockTwits ↗$MIRM Livmarli Improves Xanthomas and Hypercholesterolemia in Children with Alagille Syndrome https://www.ovid.com/journals/jped/abstract/10.1016/j.jpeds.2026.115108~maralixibat-improves-xanthomas-and-hypercholesterolemia-in?redirectionsource=fulltextview
View on StockTwits ↗
$MIRM $GOOGL $META $MELI $UBER Earnings season is revealing an important disconnect: some companies are delivering strong growth, rising revenue, improving cash flow, and higher guidance, yet their stocks are still under pressure. Alphabet, Meta, Mercado Libre, Uber, and Axon show why short-term market reactions can sometimes obscure stronger underlying fundamentals. For a long-term investor, the opportunity is not simply finding stocks that beat expectations—it is identifying businesses that continue getting stronger even when the... https://www.wizeinvesting.com/p/from-small-deposits-to-strong-results-with-mirm
View on StockTwits ↗$MIRM same as always. Made 9.5/share here so far. Weak hands. Don’t know what they own. Strong 😎 so happy for the longs here! 🥹👏
View on StockTwits ↗
$MIRM reported robust Q2 2026 net sales of $176.2 million and hiked guidance, yet MIRM stock fell sharply after the FDA asked for an additional Phase 3 study for its PSC drug volixibat. https://notreload.xyz/xy/mirum-drops-after-volixibat-phase-3-delay/
View on StockTwits ↗$MIRM jiiiiipppiiiiiiieee!!!!! Loaded up biggie today!!!! Already 5 dollars/share up!!!! Thank you weak hands! 😄😄😄😄😄😄
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.